Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$2.34 - $6.41 $32,006 - $87,675
-13,678 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$4.15 - $8.86 $192,236 - $410,412
-46,322 Reduced 77.2%
13,678 $82,000
Q2 2021

Aug 16, 2021

BUY
$11.44 - $13.57 $686,400 - $814,200
60,000 New
60,000 $814,000

Others Institutions Holding ELEV

About Elevation Oncology, Inc.


  • Ticker ELEV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,300,900
  • Market Cap $16.3M
  • Description
  • Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...
More about ELEV
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.